Thermo Fisher Scientific (TMO) Income from Continuing Operations (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Income from Continuing Operations for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 8.66% year-over-year to $1.8 billion; the trailing twelve-month figure through Jun 2026 stood at $7.0 billion (up 7.06% YoY), and the FY2025 full-year result was $6.8 billion, up 5.97% from the prior year.
• Income from Continuing Operations climbed to $1.8 billion in Q2 2026 per TMO's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $2.2 billion in Q2 2022 and bottomed at $1.3 billion in Q1 2024.
• Historically, Income from Continuing Operations has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 41.18% in 2023, then increased 18.8% in 2024.
• Over 5 years, Income from Continuing Operations stood at $1.6 billion in 2022, then climbed by 0.19% to $1.6 billion in 2023, then climbed by 11.45% to $1.8 billion in 2024, then increased by 11.67% to $2.0 billion in 2025, then retreated by 12.15% to $1.8 billion in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered $1.8 billion, $1.7 billion, and $2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.